Strategy: "The Real-World Data (RWD) Bridge for Pharma & Clinical Research"
WHO to Contact
Head of Data Science or Digital Health Lead at mid-to-large biotech and CRO (Contract Research Organization) companies who are actively moving away from siloed EHR (Electronic Health Record) data toward real-world evidence (RWE).
- Specific Target Profile: Companies in the US and EU that have recently launched or are planning Disease Management Programs, Patient Engagement Apps, or Real-World Evidence (RWE) studies.
- Examples: Insilico Medicine, Tempus, IQVIA, ForgeRock (partners), or mid-size biotechs like Acuitas Therapeutics, BioMarin (digital health division).
WHY This Strategy?
M2M APIs are often seen as "infrastructure" with low direct revenue. However, **real-world data
Top comments (0)